18F-Fallypride binding potential in patients with schizophrenia compared to healthy controls

Schizophrenia Research

Volumn 122, Issue 1-3, 2010, Pages 43-52

  Lehrer, Douglas S ^a,b   Christian, Bradley T ^c   Kirbas, Cemil ^b   Chiang, Meicheng ^a   Sidhu, Shawn ^a   Short, Holly ^a   Wang, Binquan ^b   Shi, Bingzhi ^b   Chu, King Wai ^d   Merrill, Brian ^a   Buchsbaum, Monte S ^a,b,e,f,g  

^a WRIGHT STATE UNIVERSITY   (United States)

^b Innovation Center at Kettering Health Network   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f NeuroPET Center   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cortex; Dopamine; Molecular imaging; Positron emission tomography; Schizophrenia; Thalamus

Indexed keywords

FALLYPRIDE F 18; NEUROLEPTIC AGENT; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; BENZAMIDE DERIVATIVE; DIAGNOSTIC AGENT; FLUORINE; N ((1 ALLYL 2 PYRROLIDINYL)METHYL) 5 (3 FLUOROPROPYL) 2,3 DIMETHOXYBENZAMIDE; N-((1-ALLYL-2-PYRROLIDINYL)METHYL)-5-(3-FLUOROPROPYL)-2,3-DIMETHOXYBENZAMIDE; PYRROLIDINE DERIVATIVE;

ADULT; ARTICLE; BINDING KINETICS; BRAIN CORTEX; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; HUMAN; IMAGE ANALYSIS; MALE; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCHIZOPHRENIA; THALAMUS; ADOLESCENT; ANALYSIS OF VARIANCE; BRAIN; BRAIN MAPPING; CASE CONTROL STUDY; DRUG EFFECT; METABOLISM; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROTEIN BINDING; SCINTISCANNING; STATISTICS;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; BENZAMIDES; BRAIN; BRAIN MAPPING; CASE-CONTROL STUDIES; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; PYRROLIDINES; SCHIZOPHRENIA; STATISTICS AS TOPIC; YOUNG ADULT;

EID: 77956188286     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2010.03.043     Document Type: Article

References (62)

1. Agid O., Mamo D., Ginovart N., Vitcu I., Wilson A.A., et al. Striatal vs extrastriatal dopamine D-2 receptors in antipsychotic response - a double-blind PET study in schizophrenia. Neuropsychopharmacology 2007, 32:1209-1215.
2. Ahveninen J., Jaaskelainen I.P., Raij T., Bonmassar G., Devore S., et al. Task-modulated "what" and "where" pathways in human auditory cortex. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:14608-14613.
3. Alelu-Paz R., Gimenez-Amaya J.M. The mediodorsal thalamic nucleus and schizophrenia. J. Psychiatry Neurosci. 2008, 33:489-498.
4. Andreasen N.C., Carson R., Diksic M., Evans A., Farde L., et al. Workshop on schizophrenia, PET, and dopamine D2 receptors in the human neostriatum. Schizophr. Bull. 1988, 14:471-484.
5. Andreasen N.C., Oleary D.S., Flaum M., Nopoulos P., Watkins G.L., et al. Hypofrontality in schizophrenia: distributed dysfunctional circuits in neuroleptic-naive patients. Lancet 1997, 349:1730-1734.
6. Asselin M.C., Montgomery A.J., Grasby P.M., Hume S.P. Quantification of PET studies with the very high-affinity dopamine D-2/D-3 receptor ligand [C-11]FLB 457: re-evaluation of the validity of using a cerebellar reference region. J. Cereb. Blood Flow Metab. 2007, 27:378-392.
7. Bleich-Cohen M., Hendler T., Kotler M., Strous R.D. Reduced language lateralization in first-episode schizophrenia: an fMRI index of functional asymmetry. Psychiatry Res. Neuroimaging 2009, 171:82-93.
8. Brix G., Zaers J., Adam L.E., Bellemann M.E., Ostertag H., et al. Performance evaluation of a whole-body PET scanner using the NEMA protocol. National Electrical Manufacturers Association. J. Nucl. Med. 1997, 38:1614-1623.
9. Buchsbaum M.S., Christian B.T., Lehrer D.S., Narayanan T.K., Shi B.Z., et al. D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia. Schizophr. Res. 2006, 85:232-244.
10. Christian B.T., Vandehey N.T., Fox A.S., Murali D., Oakes T.R., et al. The distribution of D2/D3 receptor binding in the adolescent rhesus monkey using small animal PET imaging. NeuroImage 2009, 44:1334-1344.
11. Comar D., Zarifian E., Verhas M., Soussaline F., Maziere M., et al. Brain distribution and kinetics of chlorpromazine-c-11 in schizophrenics - positron emission tomography studies. Psychiatry Res. 1979, 1:23-29.
12. Cunningham V.J., Hume S.P., Price G.R., Ahier R.G., Cremer J.E., Jones A.K. Compartmental analysis of diprenorphine binding to opiate receptors in the rat in vivo and its comparison with equilibrium data in vitro. J. Cereb. Blood Flow Metab. 1991, 11:1-9.
13. Delforge J., Bottlaender M., Loc'h C., Guenther I., Fuseau C., et al. Quantitation of extrastriatal D2 receptors using a very high-affinity ligand (FLB 457) and the multi-injection approach. J. Cereb. Blood Flow Metab. 1999, 19:533-546.
14. Eckelman W.C., Kilbourn M.R., Mathis C.A. Specific to nonspecific binding in radiopharmaceutical studies: it's not so simple as it seems!. Nucl. Med. Biol. 2009, 36:235-237.
15. Farde L., Wiesel F.A., Stone-Elander S., Halldin C., Nordstrom A.L., et al. D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride. Arch. Gen. Psychiatry 1990, 47:213-219.
16. Ford J.M., Roach B.J., Jorgensen K.W., Turner J.A., Brown G.G., et al. Tuning in to the voices: a multisite fMRI study of auditory hallucinations. Schizophr. Bull. 2009, 35:58-66.
17. Garcia-Cabezas M.A., Rico B., Sanchez-Gonzalez M.A., Cavada C. Distribution of the dopamine innervation in the macaque and human thalamus. NeuroImage 2007, 34:965-984.
18. Glahn D.C., Ragland J.D., Abramoff A., Barrett J., Laird A.R., et al. Beyond hypofrontality: a quantitative meta-analysis of functional neuroimaging studies of working memory in schizophrenia. Hum. Brain Mapp. 2005, 25:60-69.
19. Glenthoj B.Y., Mackeprang T., Svarer C., Rasmussen H., Pinborg L.H., et al. Frontal dopamine D-2/3 receptor binding in drug-naive first-episode schizophrenic patients correlates with positive psychotic symptoms and gender. Biol. Psychiatry 2006, 60:621-629.
20. Goldsmith S.K., Shapiro R.M., Joyce J.N. Disrupted pattern of D2 dopamine receptors in the temporal lobe in schizophrenia. a postmortem study. Arch. Gen. Psychiatry 1997, 54:649-658.
21. Hazlett E.A., Buchsbaum M.S., Haznedar M.M., Singer M.B., Germans M.K., et al. Prefrontal cortex glucose metabolism and startle eyeblink modification abnormalities in unmedicated schizophrenia patients. Psychophysiology 1998, 35:186-198.
22. Howes O.D., Kapur S. The dopamine hypothesis of schizophrenia: version III-025EFThe final common pathway. Schizophr. Bull. 2009, 35:549-562.
23. Ichise M., Toyama H., Innis R.B., Carson R.E. Strategies to improve neuroreceptor parameter estimation by linear regression analysis. J. Cereb. Blood Flow Metab. 2002, 22:1271-1281.
24. Ito H., Takahashi H., Arakawa R., Takano H., Suhara T. Normal database of dopaminergic neurotransmission system in human brain measured by positron emission tomography. NeuroImage 2008, 39:555-565.
25. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am. J. Psychiatry 2003, 160:13-23.
26. Kegeles L.S., Slifstein M., Frankle W.G., Xu X.Y., Hackett E., et al. Dose-occupancy study of striatal and extrastriatal dopamine D-2 receptors by aripiprazole in schizophrenia with PET and [F-18] Fallypride. Neuropsychopharmacology 2008, 33:3111-3125.
27. Kegeles L.S., Slifstein M., Xu X., Hackett E., Gil R., et al. D-2/D-3 receptor binding in striatal and extrastriatal regions in schizophrenia measured with [F-18]fallypride PET. 7th International Symposium on Functional Neuroreceptor Mapping of the Living Brain 2008, T52-T. Academic Press Inc Elsevier Science, Pittsburgh, PA.
28. Kessler R.M., Mason N.S., Votaw J.R., De Paulis T., Clanton J.A., et al. Visualization of extrastriatal dopamine D2 receptors in the human brain. Eur. J. Pharmacol. 1992, 223:105-107.
29. Kessler R.M., Woodward N.D., Riccardi P., Li R., Ansari M.S., et al. Dopamine D-2 receptor levels in striatum, thalamus, substantia nigra, limbic regions, and cortex in schizophrenic subjects. Biol. Psychiatry 2009, 65:1024-1031.
30. Logan J., Fowler J.S., Volkow N.D., Wang G.J., Ding Y.S., Alexoff D.L. Distribution volume ratios without blood sampling from graphical analysis of PET data. J. Cereb. Blood Flow Metab. 1996, 16:834-840.
31. Miller J., Williamson P., Jensen J.E., Manchanda R., Menon R., et al. Longitudinal 4.0Tesla P-31 magnetic resonance spectroscopy changes in the anterior cingulate and left thalamus in first episode schizophrenia. Psychiatry Res NeuroImaging 2009, 173:155-157.
32. Mitelman S.A., Shihabuddin L., Brickman A.M., Hazlett E.A., Buchsbaum M.S. MRI assessment of gray and white matter distribution in Brodmann's areas of the cortex in patients with schizophrenia with good and poor outcomes. Am. J. Psychiatry 2003, 160:2154-2168.
33. Mitelman S.A., Brickman A.M., Shihabuddin L., Newmark R., Chu K.W., Buchsbaum M.S. Correlations between MRI-assessed volumes of the thalamus and cortical Brodmann's areas in schizophrenia. Schizophr. Res. 2005, 75:265-281.
34. Mitelman S.A., Buchsbaum M.S., Brickman A.M., Shihabuddin L. Cortical intercorrelations of frontal area volumes in schizophrenia. NeuroImage 2005, 27:753-770.
35. Mukherjee J., Yang Z.Y., Das M.K., Brown T. Fluorinated benzamide neuroleptics-III. Development of (S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3-[18F]fluoropropyl)-2, 3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer. Nucl. Med. Biol. 1995, 22:283-296.
36. Mukherjee J., Yang Z.Y., Brown T., Lew R., Wernick M., et al. Preliminary assessment of extrastriatal dopamine D-2 receptor binding in the rodent and nonhuman primate brains using the high affinity radioligand, 18F-fallypride. Nucl. Med. Biol. 1999, 26:519-527.
37. Mukherjee J., Christian B.T., Dunigan K.A., Shi B.Z., Narayanan T.K., et al. Brain imaging of F-18-fallypride in normal volunteers: Blood analysis, distribution, test-retest studies, and preliminary assessment of sensitivity to aging effects on dopamine D-2/D-3 receptors. Synapse 2002, 46:170-188.
38. O'Daly O.G., Frangou S., Chitnis X., Shergill S.S. Brain structural changes in schizophrenia patients with persistent hallucinations. Psychiatry Res. Neuroimaging 2007, 156:15-21.
39. Oertel V., Rotarska-Jagiela A., van de Ven V., Haenschel C., Grube M., et al. Mental imagery vividness as a trait marker across the schizophrenia spectrum. Psychiatry Res. 2009, 167:1-11.
40. Olsson H., Halldin C., Swahn C.G., Farde L. Quantification of [11C]FLB 457 binding to extrastriatal dopamine receptors in the human brain. J. Cereb. Blood Flow Metab. 1999, 19:1164-1173.
41. Olsson H., Halldin C., Farde L. Differentiation of extrastriatal dopamine D2 receptor density and affinity in the human brain using PET. NeuroImage 2004, 22:794-803.
42. Parellada E., Lomena F., Font M., Pareto D., Gutierrez F., et al. Fluordeoxyglucose-PET study in first-episode schizophrenic patients during the hallucinatory state, after remission and during linguistic-auditory activation. Nucl. Med. Commun. 2008, 29:894-900.
43. Perry R., Oakley A., Perry E. Coronal brain map and dissection guide: localization of Brodmann areas in coronal sections 1996, Mt. Sinai School of Medicine, New York, NY.
44. Pinborg L.H., Videbaek C., Ziebell M., Mackeprang T., Friberg L., et al. [I-123]epidepride binding to cerebellar dopamine D-2/D-3 receptors is displaceable: implications for the use of cerebellum as a reference region. NeuroImage 2007, 34:1450-1453.
45. Riccardi P., Li R., Ansari M.S., Zald D., Park S., et al. Amphetamine-induced displacement of [F-18] fallypride in striatum and extrastriatal regions in humans. Neuropsychopharmacology 2006, 31:1016-1026.
46. Seok J.H., Park H.J., Chun H.W., Lee S.K., Cho H.S., et al. White matter abnormalities associated with auditory hallucinations in schizophrenia: A combined study of voxel-based analyses of diffusion tensor imaging and structural magnetic resonance imaging. Psychiatry Res. Neuroimaging 2007, 156:93-104.
47. Simeon D., Guralnik O., Hazlett E.A., Spiegel-Cohen J., Hollander E., Buchsbaum M.S. Feeling unreal: a PET study of depersonalization disorder. Am. J. Psychiatry 2000, 157:1782-+.
48. Stein D.J., Buchsbaum M.S., Hof P.R., Siegel B.V., Shihabuddin L. Greater metabolic rate decreases in hippocampal formation and proisocortex than in neocortex in Alzheimer's disease. Neuropsychobiology 1998, 37:10-19.
49. Takahashi H., Higuchi M., Suhara T. The role of extrastriatal dopamine D2 receptors in schizophrenia. Biol. Psychiatry 2006, 59:919-928.
50. Talvik M., Nordstrom A.L., Olsson H., Halldin C., Farde L. Decreased thalamic D-2/D-3 receptor binding in drug-naive patients with schizophrenia: a PET study with [C-11]FLB 457. Int. J. Neuropsychopharmacol. 2003, 6:361-370.
51. Talvik M., Nordstrom A.L., Okubo Y., Olsson H., Borg J., et al. Dopamine D-2 receptor binding in dirug-naive patients with schizophrenia examined with raclopride-C11 and positron emission tomography. Psychiatry Res. NeuroImaging 2006, 148:165-173.
52. Tune L.E., Wong D.F., Pearlson G., Strauss M., Young T., et al. Dopamine D-2 receptor density estimates in schizophrenia - a positron emission tomography study with C-11 n-methylspiperone. Psychiatry Res. 1993, 49:219-237.
53. Tuppurainen H., Kuikka J., Viinamaki H., Husso-Saastamoinen M., Bergstrom K., Tiihonen J. Extrastriatal dopamine D-2/3 receptor density and distribution in drug-naive schizophrenic patients. Mol. Psychiatry 2003, 8:453-455.
54. Tuppurainen H., Kuikka J.T., Laakso M.P., Viinamaki H., Husso M., Tiihonen J. Midbrain dopamine D-2/3 receptor binding in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 2006, 256:382-387.
55. van Haren N.E., Hulshoff Pol H.E., Schnack H.G., Cahn W., Mandl R.C., et al. Focal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up study. Neuropsychopharmacology 2007, 32:2057-2066.
56. Venkatasubramanian G. Neuroanatomical correlates of psychopathology in antipsychotic-naive schizophrenia. Indian J. Psychiatry 2010, 52:28-36.
57. Vilkman H., Kajander J., Nagren K., Oikonen V., Syvalahti E., Hietala J. Measurement of extrastriatal D-2-like receptor binding with [C-11]FLB 457 - a test-retest analysis. Eur. J. Nucl. Med. 2000, 27:1666-1673.
58. Wong D.F., Wagner H.N., Tune L.E., Dannals R.F., Pearlson G.D., et al. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science 1986, 234:1558-1563.
59. Woods R.P., Cherry S.R., Mazziotta J.C. Rapid automated algorithm for aligning and reslicing PET images. J. Comput. Assist. Tomogr. 1992, 16:620-633.
60. Yasuno F., Suhara T., Okubo Y., Sudo Y., Inoue M., et al. Low dopamine D-2 receptor binding in subregions of the thalamus in schizophrenia. Am. J. Psychiatry 2004, 161:1016-1022.
61. Yasuno F., Suhara T., Okubo Y., Ichimiya T., Takano A., et al. Abnormal effective connectivity of dopamine D2 receptor binding in schizophrenia. Psychiatry Res. NeuroImaging 2005, 138:197-207.
62. Young K.A., Randall P.K., Wilcox R.E. Startle and sensorimotor correlates of ventral thalamic dopamine and GABA in rodents. NeuroReport 1995, 6:2495-2499.